1-8 of 8 Products & Services
Detect drug induced liver injury (DILI) early in the drug discovery process with PerkinElmer's Toxicology Fluorescent Imaging Agent Panel.
Drug-induced liver injury (DILI) is the leading reason for termination of drug discovery research projects and is a significant concern in attrition of new drug molecules reaching phase III clinical trials. DILI can manifest in hepatocellular, cholestatic, and steatotic forms differing in the type and pattern of tissue injury, biomarker expression and inflammation in the liver lobules.
1-2 of 2 Resource Library